ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Taiko Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 5.99%
- The company has been able to generate a Return on Equity (avg) of 5.99% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with a -43.41% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 5.99% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -21.72% and Operating profit at -43.41% over the last 5 years
4
Flat results in Jun 26
- NET PROFIT(HY) At JPY 44 MM has Grown at -83.97%
- CASH AND EQV(HY) Lowest at JPY 6,998 MM
5
Underperformed the market in the last 1 year
- Even though the market (Japan Nikkei 225) has generated returns of 43.52% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -16.29% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Taiko Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Taiko Pharmaceutical Co., Ltd.
-16.29%
-1.18
28.58%
Japan Nikkei 225
43.52%
1.48
29.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-21.72%
EBIT Growth (5y)
-43.41%
EBIT to Interest (avg)
-178.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.64
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
17.96%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.17%
ROE (avg)
5.99%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.61
EV to EBIT
31.25
EV to EBITDA
16.65
EV to Capital Employed
2.04
EV to Sales
1.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.53%
ROE (Latest)
5.06%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NET SALES(Q)
At JPY 1,720 MM has Grown at 11.63%
-8What is not working for the Company
NET PROFIT(HY)
At JPY 44 MM has Grown at -83.97%
CASH AND EQV(HY)
Lowest at JPY 6,998 MM
Here's what is working for Taiko Pharmaceutical Co., Ltd.
Net Sales
At JPY 1,720 MM has Grown at 11.63%
over average net sales of the previous four periods of JPY 1,540.75 MMMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Depreciation
Highest at JPY 75 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Taiko Pharmaceutical Co., Ltd.
Net Profit
At JPY 44 MM has Grown at -83.97%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Cash and Eqv
Lowest at JPY 6,998 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Footer loading
